JP2002500872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500872A5 JP2002500872A5 JP2000528295A JP2000528295A JP2002500872A5 JP 2002500872 A5 JP2002500872 A5 JP 2002500872A5 JP 2000528295 A JP2000528295 A JP 2000528295A JP 2000528295 A JP2000528295 A JP 2000528295A JP 2002500872 A5 JP2002500872 A5 JP 2002500872A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune effector
- antigen
- effector cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 32
- 239000000427 antigen Substances 0.000 description 23
- 239000012642 immune effector Substances 0.000 description 22
- 229940121354 immunomodulator Drugs 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 210000004754 hybrid cell Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- -1 bone marrow or skin Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8835798P | 1998-01-26 | 1998-01-26 | |
| US60/088,357 | 1998-01-26 | ||
| US8004198P | 1998-03-31 | 1998-03-31 | |
| US60/080,041 | 1998-03-31 | ||
| PCT/US1999/001464 WO1999037313A1 (en) | 1998-01-26 | 1999-01-25 | Immune effector cell hybrids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009102653A Division JP2009195235A (ja) | 1998-01-26 | 2009-04-21 | 免疫エフェクター細胞ハイブリッド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500872A JP2002500872A (ja) | 2002-01-15 |
| JP2002500872A5 true JP2002500872A5 (enExample) | 2009-06-18 |
Family
ID=26762993
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000528295A Pending JP2002500872A (ja) | 1998-01-26 | 1999-01-25 | 免疫エフェクター細胞ハイブリッド |
| JP2009102653A Withdrawn JP2009195235A (ja) | 1998-01-26 | 2009-04-21 | 免疫エフェクター細胞ハイブリッド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009102653A Withdrawn JP2009195235A (ja) | 1998-01-26 | 2009-04-21 | 免疫エフェクター細胞ハイブリッド |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1071436A4 (enExample) |
| JP (2) | JP2002500872A (enExample) |
| AU (1) | AU2339299A (enExample) |
| CA (1) | CA2318987A1 (enExample) |
| WO (1) | WO1999037313A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142974A1 (en) * | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
| EP1168924A4 (en) * | 1999-03-31 | 2002-09-04 | Univ Pittsburgh | DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL |
| DE60226853D1 (de) * | 2001-02-20 | 2008-07-10 | Ortho Mcneil Pharm Inc | Zelltherapieverfahren für die behandlung von tumoren |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| FR2828934B1 (fr) * | 2001-08-27 | 2004-08-13 | Inst Nat Sante Rech Med | Test de l'immunite cellulaire par des peptides fixes sur support solide |
| AU2003275767A1 (en) * | 2002-11-07 | 2004-06-07 | Johnson & Johnson Research Pty Limited | A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994002156A1 (en) * | 1992-07-16 | 1994-02-03 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate t cells |
| DE69839215T2 (de) * | 1997-04-15 | 2009-03-19 | Dana-Farber Cancer Institute, Inc., Boston | Dendritische zellhybride |
-
1999
- 1999-01-25 EP EP99903347A patent/EP1071436A4/en not_active Withdrawn
- 1999-01-25 AU AU23392/99A patent/AU2339299A/en not_active Abandoned
- 1999-01-25 CA CA002318987A patent/CA2318987A1/en not_active Abandoned
- 1999-01-25 JP JP2000528295A patent/JP2002500872A/ja active Pending
- 1999-01-25 WO PCT/US1999/001464 patent/WO1999037313A1/en not_active Ceased
-
2009
- 2009-04-21 JP JP2009102653A patent/JP2009195235A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Enk et al. | Dendritic cells as mediators of tumor‐induced tolerance in metastatic melanoma | |
| EP1390474B1 (fr) | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene | |
| Schultze et al. | CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. | |
| von Bergwelt-Baildon et al. | Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application | |
| US20090226404A1 (en) | Methods for Generating Antigen-Specific Effector T Cells | |
| US7195758B2 (en) | Methods of inducing a T cell mediated immune response by administering antigen presenting B cells | |
| AU2003214566A1 (en) | Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions | |
| Toujas et al. | Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides | |
| JP2002539805A5 (enExample) | ||
| US20030134341A1 (en) | Th1 cell adoptive immunotherapy | |
| CN1353575A (zh) | 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞 | |
| EP1509244B1 (en) | New method and composition for producing a cellular allogeneic vaccine | |
| Ratta et al. | Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients | |
| US20050042751A1 (en) | Generation and use of new types of dendritic cells | |
| JP2980986B2 (ja) | 殺腫瘍性ｔリンパ球 | |
| US20030082163A1 (en) | Fused cells, methods of forming same, and therapies utilizing same | |
| CA2309313A1 (en) | Stimulation of the immune response by human dendritic cell manipulation | |
| JP2002500872A5 (enExample) | ||
| Lin et al. | Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-β: implications for dendritic cell immunization against cancer | |
| Citterio et al. | Dendritic cells as natural adjuvants | |
| JP2003521936A5 (enExample) | ||
| ES2301494T3 (es) | Celulas dendriticas activadas en presencia de hormonas glucocorticoides capaces de suprimir las respuestas de las celulas t especificas a un antigeno. | |
| Spits et al. | Cloning of human T and natural killer cells | |
| US20090060946A1 (en) | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells | |
| WO1998021314A2 (en) | Method of promoting b-cell proliferation and activation and of modulating the immune system |